Receptor tyrosine kinase involved in nervous system and probably heart development. Upon binding of its ligand NTF3/neurotrophin-3, NTRK3 autophosphorylates and activates different signaling pathways, including the phosphatidylinositol 3-kinase/AKT and the MAPK pathways, that control cell survival and differentiation
Exists in a dynamic equilibrium between monomeric (low affinity) and dimeric (high affinity) structures (By similarity). Binds SH2B2. Interacts with SQSTM1 and KIDINS220 (By similarity).
Interacts with PTPRS (PubMed:25385546). Interacts with MAPK8IP3/JIP3 (By similarity)
Widely expressed but mainly in nervous tissue. Isoform 2 is expressed at higher levels in adult brain than in fetal brain
| Cancer Type | Mutation Percentage |
|---|---|
| Central Nervous System Astrocytoma Grade Iv | 0.85% |
| Lung Adenocarcinoma | 7.33% |
| Lung Small Cell Carcinoma | 4.45% |
| Lung Squamous Cell Carcinoma | 5.17% |
| Oesophagus Adenocarcinoma | 8.05% |
| Oesophagus Squamous Cell Carcinoma | 0.47% |
| Pancreas Ductal Carcinoma | 2.52% |
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to NTRK3, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 15
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT02637687 | Solid Tumors Harboring NTRK Fusion | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | PHASE1, PHASE2 | ACTIVE_NOT_RECRUITING |
| NCT03375437 | Soft Tissue Sarcoma, Advanced Cancer, Metastatic Cancer | RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions. | NA | ACTIVE_NOT_RECRUITING |
| NCT04557813 | NTRK Family Gene Mutation | Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion | N/A | COMPLETED |
| NCT02097810 | Locally Advanced Solid Tumors, Metastatic Solid Tumors | Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. | PHASE1 | COMPLETED |
| NCT02576431 | Solid Tumors Harboring NTRK Fusion | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | PHASE2 | COMPLETED |
| NCT02920996 | Carcinoma, Non-Small-Cell Lung, Solid Tumor | Merestinib In Non-Small Cell Lung Cancer And Solid Tumors | PHASE2 | TERMINATED |
| NCT03215511 | Solid Tumors Harboring NTRK Fusion | A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer | PHASE1 | COMPLETED |
| NCT02650401 | Solid Tumors, CNS Tumors | Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | PHASE1, PHASE2 | ACTIVE_NOT_RECRUITING |
| NCT02568267 | Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Primary Brain Tumors, Renal Cell Carcinoma, Sarcomas, Salivary Gland Cancers, Adult Solid Tumor | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | PHASE2 | ACTIVE_NOT_RECRUITING |
| NCT03206931 | Solid Tumors Harboring NTRK Fusion | Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion | N/A | NO_LONGER_AVAILABLE |